HomeAIM • NYSEAMERICAN
AIM ImmunoTech Inc
add
Market news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 16.00K | -60.00% |
Operating expense | 3.63M | -37.13% |
Net income | -3.71M | 36.31% |
Net profit margin | -23.16K | -59.23% |
Earnings per share | -5.00 | 58.33% |
EBITDA | -3.56M | 37.26% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 2.25M | -79.46% |
Total assets | 6.25M | -61.41% |
Total liabilities | 10.11M | -11.07% |
Total equity | -3.86M | — |
Shares outstanding | 764.24K | — |
Price to book | -1.78 | — |
Return on assets | -121.80% | — |
Return on capital | -6,371.48% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -3.71M | 36.31% |
Cash from operations | -2.36M | 50.97% |
Cash from investing | 898.00K | 668.35% |
Cash from financing | 660.00K | -76.67% |
Net change in cash | -803.00K | 62.55% |
Free cash flow | -1.76M | 36.37% |
Previous close
$9.50
Year range
$2.51 - $11.50
Market cap
7.32M USD
Avg Volume
1.48K
P/E ratio
-
Dividend yield
-
About
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
Founded
1966
Headquarters
Website
Employees
22
